Michael McGrath

About Michael McGrath

Michael McGrath is Neuvivo's chief executive officer and a director. Neuvivo develops NP001, an experimental immune treatment for ALS. He is also an emeritus professor of medicine at the University of California, San Francisco. He co-founded Neuvivo and was its chief scientific officer at its 2021 launch, still holding that post in July 2025.

Experience

This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Michael McGrath in the role, so the role may have started earlier or lasted longer.

Neuvivo, Inc. Current

Chief Executive Officer and director

co-founder and Chief Scientific Officer (From 2021)

2021 – Present · Palo Alto, CA

Neuvivo advances NP001, an infused therapy designed to limit nerve-damaging inflammation in ALS.

UF

University of California, San Francisco Current

Emeritus Professor of Medicine

Key Colleagues at Startups

The people Michael McGrath works with at each company, as listed on that company's latest Form D.

Michael McGrath in the News

• Sep 30, 2026·Technology NetworksHow HIV Inspired Drug Development for ALS
• Jul 31, 2025·American Pharmaceutical ReviewNeuvivo Reaches Agreement with FDA on Path Forward for ALS Treatment

Sources

1. SECNeuvivo, Inc. Form D, filed Nov 13, 2026
2. P2Neuvivo — News
3. P3Neuvivo — NP001 regulatory path and John Curnutte appointment
4. P6Neuvivo — Corporate launch
5. P8PMC — The Effectiveness of NP001 on the Long-Term Survival of Patients with Amyotrophic Lateral Sclerosis
6. P11Neuvivo — About NP001